Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of Immune
Globulin Intravenous (Human) IVIG-SN™ in subjects with primary immunodeficiency diseases.
Phase:
Phase 3
Details
Lead Sponsor:
Green Cross Corporation
Collaborator:
Atlantic Research Group
Treatments:
Antibodies gamma-Globulins Immunoglobulin G Immunoglobulins Immunoglobulins, Intravenous Rho(D) Immune Globulin